Biomarkers associated with cardiometabolic risk in obesity

American Heart Hospital Journal

Volumn 9, Issue 1, 2011, Pages 28-32

  Younus, Sidra ^a   Rodgers, George ^b  

^a University Medical Center Brackenridge   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adiponectin; Biomarkers; Cardiometabolic risk; Leptin; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; LEPTIN;

ADIPONECTIN BLOOD LEVEL; ADIPOSE TISSUE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; HEALTH SURVEY; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; INCIDENCE; LEPTIN BLOOD LEVEL; METABOLIC SYNDROME X; OBESITY; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW; WEIGHT GAIN; BLOOD;

ADIPONECTIN; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; LEPTIN; OBESITY;

EID: 84555187493     PISSN: 15419215     EISSN: 17517168     Source Type: Journal    
DOI: 10.15420/ahhj.2011.9.1.28     Document Type: Review

References (22)

1. Centers for disease control and prevention (CDC), Behavior risk factor surveillance system (BRFSS). Available at: www.cdc.gov/brfss (accessed July 26, 2011)
2. Pischon T, Rimm EB. Adiponectin and risk of acute coronary syndromes: defining the obesity phenotype, Eur Heart J, 2007;28(3):274-5
3. Comuzzie AG, Tejero ME, Funahashi T, et al. The genes influencing adiponectin level also influence risk factors for metabolic syndrome and type 2 diabetes, Hum Biol, 2007;79(2):191-200
4. Grundy SM. Hypertriglyceridemia, Insulin Resistance and the Metabolic Syndrome, Am J Cardiol, 1999;83(9)B:25F-9F
5. Kotchen TA, Insulin Resistance and Hypertension. Hypertension and the Kidney, 1999. Available online at: www.kidneyatlas.org/book3/adk3-05.QXD.pdf (accessed July 26, 2011)
6. Cirillo P, Angri V, De Rosa S, Calì G, et al. Pro-atherothrombotic effects of leptin in human coronary endothelial cells, Thromb Haemost, 2010;103(5):1065-75
7. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women, JAMA, 1997;277(8): 642-5
8. Kajikawa Y, Ikeda M, Takemoto S, et al. Association of circulating levels of leptin and adiponectin with metabolic syndrome and coronary heart disease in patients with coronary risk factors, Int Heart J, 2011;52(1):17-22
9. Karaduman M, Oktenli C, Musabak U, et al. Leptin, soluble interleukin-6 receptor, C-reactive protein and soluble vascular adhesion molecule-1 levels in human coronary atherosclerotic plaque, Clin Exp Immunol, 2006;143(3):452-7
10. SMartin SS, Qasim A, Reilly MP. Leptin Resistance. A possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J AM Coll Cardiol, 2008;52:1201-10
11. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in The West of Scotland Coronary Prevention Study (WOSCOPS), Circulation, 2001;104(25):3052-6
12. Saely CH, Risch L, Hoefle G, et al. Low serum adiponectin is independently associated with both the metabolic syndrome and angiographically determined coronary atherosclerosis, Clin Chim Acta, 2007;(1-2):97-102
13. Ornstein RM, Jacobson MS. Supersize Teens: The Metabolic Syndrome, Adolesc Med, 2006;17:565-87
14. Shioji K, Moriwaki S, Takeuchi Y, et al. Relationship of serum adiponectin level to adverse cardiovascular events in patients who undergo percutaneous coronary intervention, Circ J, 2007;71(5):675-80
15. Hung WC, Wang CP, Lu LF, et al. Circulating adiponectin level is associated with major adverse cardiovascular events in type 2 Diabetic patients with coronary artery disease, Endocr J, 2010;57(9):793-802
16. Barseghian A, Gawande D, Bajaj M. Adiponectin and vulnerable atherosclerotic and vulnerable atherosclerotic plaques, J Am Coll Cardiol, 2011;57:761-70
17. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 Diabetes Mellitus by changes in life style among subjects with impaired glucose tolerance, N Engl J Med, 2001;344(18):1343-50
18. Krysiak R, Sierant M, Marek B, et al. The effect of angiotensinconverting enzyme inhibitors on plasma adipokine levels in normotensive patients with coronary artery disease, Endokrynol Pol, 2010;61(3):280-7
19. Ohashi T, Shibata R, Morimoto T, et al. Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study, Atherosclerosis, 2010;212(1):237-42
20. Sugiyama S, Fukushima H, Kugiyama K, et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease, Atherosclerosis, 2007;194(2):e43-51
21. Ogasawara D, Shite J, Shinke T, et al. Pioglitazone reduces the necrotic-core component in corornary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus, Circ J, 2009;73(2):343-51
22. Batsis JA, Romero-Corral A, et al. Effect of bariatric surgery on the metabolic syndrome: a population based, long term controlled study, Mayo Clin Proc, 2008;83(8):897-907